Literature DB >> 23507415

Carbapenem susceptibilities and non-susceptibility concordance to different carbapenems amongst clinically important Gram-negative bacteria isolated from intensive care units in Taiwan: results from the Surveillance of Multicentre Antimicrobial Resistance in Taiwan (SMART) in 2009.

Shio-Shin Jean1, Po-Ren Hsueh, Wen-Sen Lee, Kwok-Woon Yu, Chun-Hsing Liao, Feng-Yi Chang, Wen-Chien Ko, Jiunn-Jong Wu, Yen-Hsu Chen, Yao-Shen Chen, Jien-Wei Liu, Min-Chi Lu, Cheng-Yi Liu, Carlos Lam, Ray-Jade Chen.   

Abstract

To investigate the in vitro susceptibilities to various carbapenems amongst clinical Gram-negative bacteria isolated from patients in intensive care units of ten major teaching hospitals in Taiwan in 2009, a survey was conducted to determine the minimum inhibitory concentrations (MICs) of ertapenem, imipenem, meropenem and doripenem against isolates of Enterobacteriaceae (n = 594), Pseudomonas aeruginosa (n = 185), Acinetobacter baumannii (n = 192) and Burkholderia cepacia (n = 23) using the agar dilution method. Susceptibilities were determined according to 2009, 2011 and 2012 MIC breakpoints recommended by the CLSI as well as 2012 MIC breakpoints recommended by EUCAST. Based on CLSI 2012 criteria, the ertapenem susceptible rate was 93%, 81%, 68% and 92% for Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae and Serratia marcescens, respectively. All Proteus mirabilis and Morganella morganii isolates were susceptible to ertapenem; however, 64% of P. mirabilis and all M. morganii isolates were non-susceptible to imipenem. Meropenem and doripenem had better activities than imipenem against ertapenem-non-susceptible Enterobacteriaceae isolates. E. coli, K. pneumoniae and E. cloacae with ertapenem MICs≥4 mg/L were synchronously not susceptible to imipenem, meropenem and doripenem. Imipenem susceptibility was 65% and 29% for P. aeruginosa and A. baumannii, respectively. Additionally, P. aeruginosa and A. baumannii isolates with imipenem MICs≥8 mg/L were also not susceptible to meropenem and doripenem. These data provide a better understanding of choosing appropriate carbapenem agents to treat infections caused by ertapenem-non-susceptible Enterobacteriaceae as well as P. aeruginosa and A. baumannii isolates with imipenem MICs≥4 mg/L.
Copyright © 2013 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23507415     DOI: 10.1016/j.ijantimicag.2013.02.001

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  10 in total

1.  Carbapenem Breakpoints for Acinetobacter baumannii Group: Supporting Clinical Outcome Data from Patients with Bacteremia.

Authors:  Yi-Tzu Lee; Mei-Chun Chiang; Shu-Chen Kuo; Yung-Chih Wang; I-Hsin Lee; Te-Li Chen; Ya-Sung Yang
Journal:  PLoS One       Date:  2016-09-19       Impact factor: 3.240

2.  Susceptibility rates of clinically important bacteria collected from intensive care units against colistin, carbapenems, and other comparative agents: results from Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART).

Authors:  Chih-Cheng Lai; Ying-Sheng Chen; Nan-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-14       Impact factor: 4.003

3.  Antimicrobial activities of ceftazidime-avibactam, ceftolozane-tazobactam, and other agents against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan in 2016.

Authors:  Chun-Hsing Liao; Na-Yao Lee; Hung-Jen Tang; Susan Shin-Jung Lee; Chin-Fu Lin; Po-Liang Lu; Jiunn-Jong Wu; Wen-Chien Ko; Wen-Sen Lee; Po-Ren Hsueh
Journal:  Infect Drug Resist       Date:  2019-03-04       Impact factor: 4.003

4.  In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa.

Authors:  Katherine Young; Ronald E Painter; Susan L Raghoobar; Nichelle N Hairston; Fred Racine; Douglas Wisniewski; Carl J Balibar; Artjohn Villafania; Rumin Zhang; Daniel F Sahm; Timothy Blizzard; Nicholas Murgolo; Milton L Hammond; Mary R Motyl
Journal:  BMC Microbiol       Date:  2019-07-04       Impact factor: 3.605

5.  Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.

Authors:  Patrice Nordmann; Laurent Poirel
Journal:  Clin Infect Dis       Date:  2019-11-13       Impact factor: 9.079

Review 6.  Global Threat of Carbapenem-Resistant Gram-Negative Bacteria.

Authors:  Shio-Shin Jean; Dorji Harnod; Po-Ren Hsueh
Journal:  Front Cell Infect Microbiol       Date:  2022-03-15       Impact factor: 5.293

7.  Comparative Genomics Revealed Fluoroquinolone Resistance Determinants and OmpF Deletion in Carbapenem-Resistant Escherichia coli.

Authors:  Wan-Ting Yang; I-Ju Chiu; Yao-Ting Huang; Po-Yu Liu
Journal:  Front Microbiol       Date:  2022-04-18       Impact factor: 6.064

8.  Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.

Authors:  Jann-Tay Wang; Pei-Chen Chen; Shan-Chwen Chang; Yih-Ru Shiau; Hui-Ying Wang; Jui-Fen Lai; I-Wen Huang; Mei-Chen Tan; Tsai-Ling Yang Lauderdale
Journal:  BMC Infect Dis       Date:  2014-09-05       Impact factor: 3.090

9.  Treatment outcomes of patients with non-bacteremic pneumonia caused by extensively drug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex isolates: Is there any benefit of adding tigecycline to aerosolized colistimethate sodium?

Authors:  Shio-Shin Jean; Tai-Chin Hsieh; Wen-Sen Lee; Po-Ren Hsueh; Chin-Wan Hsu; Carlos Lam
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

Review 10.  Epidemiology, Treatment, and Prevention of Nosocomial Bacterial Pneumonia.

Authors:  Shio-Shin Jean; Yin-Chun Chang; Wei-Cheng Lin; Wen-Sen Lee; Po-Ren Hsueh; Chin-Wan Hsu
Journal:  J Clin Med       Date:  2020-01-19       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.